Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
A phase 3 trial of Savolitinib in non-small-cell lung cancer and small-cell lung cancer, run by Hutchmed, active and no longer recruiting.
Overview
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC is a phase 3 interventional study registered as NCT05009836 by Hutchmed, with 412 participants planned, started 2021-09-06 and due to reach its primary completion in 2028-05-30. Interventions recorded: Savolitinib, Placebo. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- PersonWeiguo Su
Shares Savolitinib, Hutchmed.
- TrialA Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
Shares Savolitinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialOsimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Shares Savolitinib, Hutchmed.
- TrialSavolitinib vs. Sunitinib in MET-driven PRCC.
Shares Savolitinib, Hutchmed.
- TrialPhase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Shares Savolitinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSavolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Shares Savolitinib, Non-small-cell lung cancer.
- PathwayNon-small cell lung cancer (KEGG map)
Shares Savolitinib, Non-small-cell lung cancer.